Sector commentary

Sector report cover
Alternative Energy

11/11/2014
Deutsche Börse Eigenkapitalforum 2014 Research Guide
Download via: Website

Welcome to the Edison research guide for the Deutsche Börse Eigenkapitalforum 2014. Edison is delighted to be a partner for this event for the third time. This book profiles 75 companies that will be presenting at the Eigenkapitalforum. Connecting a large number of investors with a broad range of companies in a forum like this is more important than ever. Being able to discuss the business model and outlook directly with management is hugely important for investors to identify value. In the same way, it offers quality companies the chance to stand out of the crowd and attract new investors. Thanks to all those who took the time and effort to communicate with Edison’s analysts – your contributions are reflected in the quality of this year’s research guide. The guide opens with a market strategy piece and includes an overview of each sector, as well as conference programme and maps. The company profiles include: • a discussion of the company’s strategy and market position; • a review of the business’s recent financial performance; and • a discussion on valuation based on consensus or Edison estimates. Hard copies of this guide will be available at the forum. Edison is Europe's leading investment intelligence firm, setting the standards for investor interaction with corporates. Our team of over 120 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 450 retained corporate and 60 investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Our research can be accessed free of charge at http://www.edisongroup.com.

read more...

Companies mentioned
Heartland New Zealand , Adler Real Estate , ifa systems , CENIT , Grand City Properties , StemCells , Tipp24 , InVision , SinnerSchrader , Erytech Pharma , Sartorius , Nanogate , Leifheit , Lanxess , Albioma , aap Implantate AG , Prosensa , Thin Film Electronics , Fair Value REIT , artnet , Grammer , Newron Pharmaceuticals , GFT Group , Mologen AG , Deutsche Börse , Global Bioenergies , Sygnis , Firstextile , Seven Principles , PSI , TXT e-solutions , BB Biotech , MagForce , Medigene , Stratec Biomedical , Deutsche Beteiligungs , Transgene , Neovacs , MorphoSys , 4SC , Evotec , Epigenomics , Innovation Group , Wilex , Paion , Primary Health Properties , See more..., Takkt, Lotto 24, SYZYGY, Aurelius, Vietnam Holding, DO Deutsche Office, PATRIZIA Immobilien, SFC Energy, Wacker Chemie, PVA TePla, Arbonia Forster Holding, Durr, INDUS Holding, KTG Energy, Phoneix Solar, Technotrans, CropEnergies, NeoStem, All for One Steeb, DATAGROUP, First Sensor, Jenoptik, Mensch and Machine Software, REALTEACH, Reply SpA, SNP AG, Wincor Nixdorf, Activia Resources, TransGlobe Energy

Sector report cover
Technology

15/10/2014
German Mittelstand Conference
Download via: Website

Welcome to the Edison research guide for the OktoberINVESTfest. Edison is delighted to be a partner for this event for the second time. This book profiles the 14 German and 13 American companies presenting at the Invest in Bavaria forum in New York on 20 October 2014.

read more...

Companies mentioned
ifa systems , GFT Group , PSI

Sector report cover
Pharmaceutical & Healthcare

13/10/2014
ASX Spotlight Conference book
Download via: Website

Edison Investment Research is delighted to be working with ASX on its upcoming Spotlight Conferences in Singapore and Hong Kong on the 21 and 23 October. Below please find a link to the report Edison has produced for the event. It features profiles for each of the participating companies. We would like to thank ASX and the companies involved for their cooperation.

read more...

Companies mentioned
Benitec Biopharma , Bionomics

Sector report cover
Technology

06/10/2014
Mobile ecosystems
Download via: Website

The heady days are over. Growth is slowing and competition is growing. There has always been opportunity for change in the mobile industry but both Apple and Google seem to have found the holes in the armour and are moving to address their weaknesses. This puts a time limit on any challenger as the risk is that these two become so big and so ubiquitous that users cannot be bothered to look elsewhere.

read more...

Companies mentioned

Sector report cover
Oil & Gas

27/08/2014
Onshore down under - Oil & gas sector report
Download via: Website

The evolution of the Australian onshore unconventional sector is nearing the sharp end. JVs are largely bedded down, key work programmes are mapped and funded, and the next two years is about execution. In this report we update our August 2013 report by tracking progress of a subset of onshore players. We review macro developments, track well and seismic activity and compare deal flow with our previous report. We also analyse equity performance, and assess how the market has moved relative to company progress. Short-term investor focus appears to be on take-over targets, but we think that focus will revert to activity. With the Cooper Basin programmes in full swing, the event horizon may not be far off. Medium-term focus is on those driving the activity, while investing in the resource plays is more about longer-term positioning.

read more...

Companies mentioned

Sector report cover
Pharmaceutical & Healthcare

30/06/2014
Edison healthcare quarterly: It’s getting personal
Download via: Website

Welcome to the Edison healthcare quarterly, which contains profiles of 75 companies under coverage. The book opens with an overview of biomarker programmes within drug development by Philippa Gardner, and the challenges and opportunities these present for the pharma and biotech industry. Incorporating a biomarker programme into drug development with the aim of identifying companion diagnostics (CDx) could offer a number of advantages. These include the ability to identify patients most likely to respond to or better tolerate a given agent, potentially improving the chances of clinical success, regulatory approval and reimbursement from healthcare payers. However, it is only recently that the rate of development and regulatory approvals for targeted agent/diagnostic combinations has accelerated. Herceptin was the flagship for the CDx field and unsurprisingly, the majority of drugs with a requirement for genetic testing remain in cancer. However, biomarker development is broadening to other indications, and companies now seem to be more proactively considering biomarker development at earlier stages of development.

read more...

Companies mentioned
Simavita , Verisante Technology , Regeneus , TESARO , SQI Diagnostics , Cardio3 BioSciences , Erytech Pharma , Onconova Therapeutics , Can-Fite BioPharma , aap Implantate AG , BioAlliance Pharma , Bellus Health , Mesoblast , Newron Pharmaceuticals , Athersys , DBV Technologies , Mologen AG , Derma Sciences , Sygnis , ArQule , Clinigen , Prima BioMed , LeMaitre Vascular , Cytori Therapeutics , CytRx Corporation , Hutchison China MediTech , Diaxonhit , Proteome Sciences , BioLineRx , TiGenix , MagForce , Orexo , BioInvent , Medigene , Arrowhead Research Corporation , Alexza Pharmaceuticals , Stratec Biomedical , Phylogica , Bavarian Nordic , Dechra Pharmaceuticals , e-Therapeutics , Neovacs , MorphoSys , Evolva , 4SC , Hybrigenics , Evotec , Bionomics , Topotarget , Oncolytics Biotech Inc , Omega Diagnostics Group , Vernalis , Wilex , Paion , Biotie Therapies Corp , Consort Medical , Allergy Therapeutics , Deltex Medical , Oxford BioMedica , GW Pharmaceuticals , Lombard Medical Technologies , BTG , Skyepharma , Futura Medical

Sector report cover
Oil & Gas

02/05/2014
Oil & gas macro outlook: Ukraine supports prices for now
Download via: Website

The trend in international oil prices has been less than robust in early 2014 but firmer than fundamentals might have suggested. Once again, the explanation is geopolitical developments, with Ukraine very much to the fore of late (see pg 6). The Ukraine crisis, however, is unlikely to intensify to the extent necessary to disrupt Russian exports. Neither Russia nor the west could afford such a cataclysmic event, although it is possible that a low-level crisis over Ukraine lingers for some time. We continue to believe that the medium-term outlook is bearish for oil, reflecting burgeoning non-OPEC supplies, the upward trend in Iraq production and likely modest demand growth. A key area of medium-term uncertainty relates to the response of OPEC to rising non-OPEC and Iraqi output.

read more...

Companies mentioned

Sector report cover
Pharmaceutical & Healthcare

05/03/2014
Edison healthcare quarterly: A boost for allergy immunotherapy
Download via: Website

Welcome to the Edison healthcare quarterly, which contains profiles of 77 companies under coverage. The book opens with an overview of allergy immunotherapy by Lala Gregorek. Investor interest in allergy immunotherapy (AIT) has been revived by the announcement of Circassia's intended £200m IPO on the London Stock Exchange coupled with positive FDA Advisory Committee (AdCom) recommendations for the approval of three respiratory allergy immunotherapy tablets. These AdCom discussions also have important repercussions for the wider therapeutic modality. The expert panel confirmed significant US market potential for novel AITs and provided insight into FDA requirements for trial design and approval of respiratory AIT products, facilitating the path to approval for other companies looking to enter the US market, including Circassia.

read more...

Companies mentioned
TESARO , SQI Diagnostics , Cardio3 BioSciences , Erytech Pharma , Onconova Therapeutics , Can-Fite BioPharma , aap Implantate AG , Bionor Pharma , Viralytics , BioAlliance Pharma , Bellus Health , Nanobiotix , Mesoblast , Athersys , DBV Technologies , Mologen AG , Derma Sciences , OvaScience , Sygnis , ArQule , Clinigen , LeMaitre Vascular , Cytori Therapeutics , CytRx Corporation , Cytos Biotechnology , Hutchison China MediTech , NovaBay Pharmaceuticals , Diaxonhit , Proteome Sciences , BioLineRx , TiGenix , MagForce , Orexo , BioInvent , Medigene , Arrowhead Research Corporation , Alexza Pharmaceuticals , Aastrom Biosciences , Sunesis Pharmaceuticals , Stratec Biomedical , Innate Pharma , Phylogica , Circadian Technologies , Transgene , Bavarian Nordic , Synta Pharmaceuticals , e-Therapeutics , Neovacs , MorphoSys , Evolva , 4SC , Hybrigenics , Ablynx , Evotec , Addex Therapeutics , Bionomics , Medcom Tech , Topotarget , Epigenomics , Oncolytics Biotech Inc , Omega Diagnostics Group , Vernalis , Wilex , Paion , Biotie Therapies Corp , Consort Medical , Allergy Therapeutics , Deltex Medical , Oxford BioMedica , GW Pharmaceuticals , Lombard Medical Technologies , BTG , Skyepharma , Imperial Innovations , Animalcare Group , Futura Medical